Advertisement
Canada markets open in 5 hours 9 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7312
    +0.0014 (+0.20%)
     

  • CRUDE OIL

    83.18
    +0.37 (+0.45%)
     

  • Bitcoin CAD

    87,676.48
    -3,395.22 (-3.73%)
     

  • CMC Crypto 200

    1,322.25
    -60.33 (-4.36%)
     

  • GOLD FUTURES

    2,339.90
    +1.50 (+0.06%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,483.25
    -181.25 (-1.03%)
     

  • VOLATILITY

    16.21
    +0.24 (+1.50%)
     

  • FTSE

    8,082.02
    +41.64 (+0.52%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6815
    -0.0004 (-0.06%)
     

Exploring the Financial Performance of Akcea Therapeutics

Kenneth Smith
Updated
Exploring the Financial Performance of Akcea Therapeutics

The company generated this revenue from research and development under a collaboration agreement with Novartis (NVS). In 2018, Akcea Therapeutics is expected to generate revenue of $71.3 million, while its peers Amgen (AMGN), Ionis Pharmaceuticals (IONS), and bluebird bio (BLUE) are expected to generate revenues of $22.5 billion, $582.4 million, and $23.9 million, respectively. In 2017, Akcea Therapeutics incurred research and development expenses of $126.8 million compared to $68.4 million in 2016.

Continue reading